MX348286B - Polipeptidos de receptor de activina variantes y usos de los mismos. - Google Patents

Polipeptidos de receptor de activina variantes y usos de los mismos.

Info

Publication number
MX348286B
MX348286B MX2015002054A MX2015002054A MX348286B MX 348286 B MX348286 B MX 348286B MX 2015002054 A MX2015002054 A MX 2015002054A MX 2015002054 A MX2015002054 A MX 2015002054A MX 348286 B MX348286 B MX 348286B
Authority
MX
Mexico
Prior art keywords
receptor polypeptides
variant
activin receptor
variant activin
present
Prior art date
Application number
MX2015002054A
Other languages
English (en)
Inventor
Sun Jeonghoon
Tony Tam Lei-Ting
Han Hq
Soo-Nyung Kwak Keith
Zhou Xiaolan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX348286B publication Critical patent/MX348286B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invención se refiere a una proteína aislada, caracterizada porque comprende una variante de polipéptido del receptor de actividad IIB (vActRIIB), en donde dicho polipéptido tiene al menos 90% de identidad con polipéptido que tiene la secuencia de polipéptidos establecida en los aminoácidos 25 a 134 de SEQ ID NO:18, a excepción de una sustitución de aminoácidos en la posición 28, en donde la sustitución en la posición 28 se selecciona de cualquiera de A, F, Q, V, I, L, M, K, H, W e Y por E, y en donde el polipéptido es capaz de unirse a miostatina, activina A, o GDF-11.
MX2015002054A 2007-03-06 2008-03-06 Polipeptidos de receptor de activina variantes y usos de los mismos. MX348286B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90545907P 2007-03-06 2007-03-06
US6547408P 2008-02-11 2008-02-11
PCT/US2008/003119 WO2008109167A2 (en) 2007-03-06 2008-03-06 Variant activin receptor polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX348286B true MX348286B (es) 2017-06-02

Family

ID=39739001

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015002054A MX348286B (es) 2007-03-06 2008-03-06 Polipeptidos de receptor de activina variantes y usos de los mismos.
MX2017005686A MX389715B (es) 2007-03-06 2008-03-06 Polipéptidos de receptor de activina variantes y usos de los mismos.
MX2009009495A MX2009009495A (es) 2007-03-06 2008-03-06 Polipeptidos de receptor de activina variantes y usos de los mismos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2017005686A MX389715B (es) 2007-03-06 2008-03-06 Polipéptidos de receptor de activina variantes y usos de los mismos.
MX2009009495A MX2009009495A (es) 2007-03-06 2008-03-06 Polipeptidos de receptor de activina variantes y usos de los mismos.

Country Status (29)

Country Link
US (5) US7947646B2 (es)
EP (2) EP2132314B1 (es)
JP (1) JP5496682B2 (es)
KR (5) KR20090127146A (es)
CN (2) CN101679980B8 (es)
AR (1) AR065611A1 (es)
AU (1) AU2008223338C9 (es)
BR (1) BRPI0808332A2 (es)
CA (1) CA2679841C (es)
CL (2) CL2008000664A1 (es)
CR (2) CR11054A (es)
CY (1) CY1118857T1 (es)
DK (1) DK2132314T3 (es)
EA (2) EA201490822A1 (es)
ES (1) ES2613043T3 (es)
HR (1) HRP20170323T1 (es)
HU (1) HUE032260T2 (es)
IL (2) IL200605A (es)
LT (1) LT2132314T (es)
MX (3) MX348286B (es)
NZ (1) NZ579369A (es)
PE (3) PE20130615A1 (es)
PH (1) PH12013502308A1 (es)
PL (1) PL2132314T3 (es)
PT (1) PT2132314T (es)
RS (1) RS55726B1 (es)
SI (1) SI2132314T1 (es)
TW (3) TWI573802B (es)
WO (1) WO2008109167A2 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3059245B1 (en) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
WO2007044411A2 (en) 2005-10-06 2007-04-19 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
MX2008006626A (es) 2005-11-23 2008-09-24 Acceleron Pharma Inc Antagonistas de activin-actriia y usos para promover el crecimiento de huesos.
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
HRP20130320T1 (en) 2006-09-05 2013-05-31 Eli Lilly And Company Anti-myostatin antibodies
PL2124999T3 (pl) 2006-12-18 2013-03-29 Acceleron Pharma Inc Antagoniści aktywiny-actrii i zastosowania do leczenia niedokrwistości
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2008094708A2 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI606062B (zh) 2007-02-09 2017-11-21 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
WO2009038745A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HRP20191109T1 (hr) 2008-08-14 2019-09-20 Acceleron Pharma Inc. Gdf klopke za uporabu u liječenju anemije
AU2013216639B2 (en) * 2008-11-26 2016-05-05 Amgen Inc. Variants of activin IIB receptor polypeptides and uses thereof
LT2370463T (lt) * 2008-11-26 2016-12-12 Amgen Inc. Stabilizuotas aktivino iib receptoriaus variantas
AU2016210719B2 (en) * 2008-11-26 2018-03-29 Amgen Inc. Variants of activin IIB receptor polypeptides and uses thereof
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
SG174273A1 (en) 2009-04-27 2011-10-28 Novartis Ag Compositions and methods for increasing muscle growth
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
EP3260130B1 (en) * 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
CA2781152A1 (en) * 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
SG10201506405YA (en) 2010-08-16 2015-10-29 Amgen Inc Polypeptides That Bind Myostatin, Compositions And Methods
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ， インコーポレイテッド Ａｃｔｒｉｉａ結合剤およびその使用
CN107028789A (zh) 2010-11-12 2017-08-11 高露洁—棕榄公司 口腔护理产品及其使用和制备方法
WO2013006437A1 (en) * 2011-07-01 2013-01-10 Novartis Ag Method for treating metabolic disorders
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
WO2013074557A1 (en) 2011-11-14 2013-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
EP2793925B1 (en) * 2011-12-19 2019-03-20 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
JP6124986B2 (ja) * 2012-03-19 2017-05-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 拡張期心不全を処置するための増殖分化因子（ｇｄｆ）
US9453080B2 (en) 2012-06-11 2016-09-27 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
AU2013334660B2 (en) 2012-10-24 2018-08-09 Celgene Corporation Methods for treating anemia
ES2884095T3 (es) 2012-11-02 2021-12-10 Celgene Corp Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
EP3985024A1 (en) 2013-02-01 2022-04-20 Atara Biotherapeutics, Inc. Anti-activin-a compounds for the treatment of ovarian cancer
KR20150140294A (ko) * 2013-03-15 2015-12-15 암젠 인코퍼레이티드 사람 대상에서 미오스타틴 길항작용
JP2016518357A (ja) 2013-04-08 2016-06-23 プレジデント アンド フェローズ オブ ハーバード カレッジ 骨格筋幹細胞を若返らせる方法および組成物
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
US10017566B2 (en) 2013-11-12 2018-07-10 The Brigham And Women's Hospital, Inc. Growth differentiation factor (GDF) for treatment of diastolic heart failure
CA2952231A1 (en) * 2014-06-13 2015-12-17 Santa Maria Biotherapeutics, Inc. Formulated receptor polypeptides and related methods
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA41052A (fr) * 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
AU2015358469B2 (en) 2014-12-03 2021-05-27 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for treating anemia
US20170260275A1 (en) * 2014-12-08 2017-09-14 Novartis Ag Myostatin or activin antagonists for the treatment of sarcopenia
WO2016128523A1 (en) 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
US9744985B2 (en) 2015-02-17 2017-08-29 Hyundai Motor Company Rack bar unit of vehicle steering device
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
EP3828199B1 (en) 2015-04-06 2025-10-15 Acceleron Pharma Inc. Alk7: actriib heteromultimers and uses thereof
CN107849114B (zh) 2015-04-06 2021-08-20 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
EP3283519A1 (en) 2015-04-15 2018-02-21 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
SG10201913747PA (en) 2015-04-22 2020-03-30 Biogen Ma Inc Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
RU2651776C2 (ru) * 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
JP6948331B2 (ja) 2016-01-06 2021-10-13 プレジデント アンド フェローズ オブ ハーバード カレッジ Ｇｄｆ１１での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する
PL3426680T3 (pl) 2016-03-10 2025-03-31 Acceleron Pharma Inc. Białka wiążące receptor aktywiny typu 2 i ich zastosowania
CA3039573A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Alk4:actriib heteromultimers and uses thereof
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
JP7258021B2 (ja) 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体を含む医薬組成物
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
IL321873A (en) 2018-03-01 2025-08-01 Regeneron Pharma Methods for altering body composition
CN112601538B (zh) 2018-05-09 2025-08-19 科乐斯疗法公司 激活素受体iia型变体及其使用方法
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4444747A1 (en) * 2021-12-10 2024-10-16 Biogen MA Inc. Modified actriib proteins and methods of use thereof

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899886A (en) * 1959-08-18 rodth
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5349966A (en) 1976-10-18 1978-05-06 Hitachi Ltd Manufacture of semiconductor integrated circuit
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
ES2096677T3 (es) * 1991-07-05 1997-03-16 Nestle Sa Cartucho rigido para cafe y su procedimiento de fabricacion.
ATE129616T1 (de) * 1991-07-05 1995-11-15 Nestle Sa Gerät zum extrahieren von kartuschen, brauchbar für jede espressomaschine.
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
WO1994021681A1 (en) 1993-03-19 1994-09-29 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
WO1995030003A2 (en) 1994-04-29 1995-11-09 Creative Biomolecules, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2288036T5 (es) 1998-11-13 2017-07-06 Immunex Corporation ADN de TSLP humano y polipéptidos
CA2359242C (en) 1999-01-21 2009-12-08 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
JP2000262405A (ja) * 1999-03-18 2000-09-26 Soc Prod Nestle Sa 飲料抽出用密封カートリッジ
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
TWI236360B (en) * 2000-06-30 2005-07-21 Nestle Sa Capsule cage
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
DK1190959T3 (da) * 2000-09-26 2004-06-28 Nestle Sa Lukket indsats, der er beregnet til fremstilling af en drik ved udtrækning under tryk
EP1203554A1 (fr) * 2000-11-03 2002-05-08 Societe Des Produits Nestle S.A. Dispositif pour l'extraction d'une substance alimentaire contenue dans un élément de recharge
TR200402491T4 (tr) * 2000-11-28 2004-12-21 Societe Des Produits Nestle S.A. Süzme tertibatı.
US20050188854A1 (en) * 2002-02-07 2005-09-01 The Coca-Cola Co. Coffee and tea dispenser
US6786134B2 (en) * 2002-02-07 2004-09-07 The Coca-Cola Company Coffee and tea dispenser
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
FR2842092B1 (fr) * 2002-07-12 2004-12-24 Seb Sa Machine a cafe fonctionnant avec des doses
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
ES2359562T3 (es) 2002-12-20 2011-05-24 Amgen, Inc. Agentes de unión que inhiben miostatina.
KR20060026860A (ko) 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도
US8327754B2 (en) * 2003-07-22 2012-12-11 The Coca-Cola Company Coffee and tea pod
US20060196364A1 (en) * 2003-07-22 2006-09-07 The Coca-Cola Company Coffee & Tea Pod
HUE044822T2 (hu) 2003-09-12 2019-11-28 Amgen Inc Cinakalcet HCl gyors feloldódású készítménye
US7074445B2 (en) * 2003-10-30 2006-07-11 Frito-Lay North America, Inc. Method for adhering large seasoning bits to a food substrate
ES2438098T3 (es) 2003-11-13 2014-01-15 Hanmi Science Co., Ltd. Composición farmacéutica que comprende un Fc de inmunoglobulina como vehículo
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
GB2411106B (en) * 2004-02-17 2006-11-22 Kraft Foods R & D Inc Cartridge for the preparation of beverages
PT1750683E (pt) 2004-04-23 2013-01-25 Amgen Inc Formulações de libertação sustida
EP3059245B1 (en) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
GB2416480B (en) * 2004-07-27 2007-12-27 Kraft Foods R & D Inc A system for the preparation of beverages
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
DK1797127T3 (en) 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
EP1640756A1 (en) * 2004-09-27 2006-03-29 Barco N.V. Methods and systems for illuminating
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
MY164457A (en) 2005-09-07 2017-12-15 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like kinase-1
EP1775234B1 (en) * 2005-10-14 2008-07-30 Nestec S.A. Capsule for the preparation of a beverage
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20080014860A1 (en) * 2006-07-14 2008-01-17 Lynn Byron Heitman Method and apparatus for eliminating register boxes, improving penetration sealing, improving airflow and reducing the labor costs to install ceiling registers
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
PL2124999T3 (pl) 2006-12-18 2013-03-29 Acceleron Pharma Inc Antagoniści aktywiny-actrii i zastosowania do leczenia niedokrwistości
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI573802B (zh) * 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
WO2008113185A1 (en) 2007-03-19 2008-09-25 National Research Counsil Of Canada Antagonists of ligands and uses thereof
US8431175B2 (en) * 2007-06-05 2013-04-30 Nestec S.A. Method for preparing a beverage or food liquid and system using brewing centrifugal force
JP5082676B2 (ja) * 2007-08-23 2012-11-28 株式会社サタケ 光学式穀物選別機
WO2009038745A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
CA2729096C (en) 2008-06-26 2020-04-28 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
AU2009268116B2 (en) * 2008-07-08 2015-01-29 Société des Produits Nestlé S.A. Portion-controlled nutrition system and method using capsules
US8151694B2 (en) * 2008-08-01 2012-04-10 Keurig, Incorporated Beverage forming apparatus with centrifugal pump
HRP20191109T1 (hr) 2008-08-14 2019-09-20 Acceleron Pharma Inc. Gdf klopke za uporabu u liječenju anemije
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US8512784B2 (en) * 2008-09-02 2013-08-20 Nestec S.A. Method and device for controlled beverage production using centrifugal forces
LT2370463T (lt) 2008-11-26 2016-12-12 Amgen Inc. Stabilizuotas aktivino iib receptoriaus variantas
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
SG174273A1 (en) 2009-04-27 2011-10-28 Novartis Ag Compositions and methods for increasing muscle growth
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
US20120295814A1 (en) 2010-01-08 2012-11-22 The Brigham And Women's Hospital, Inc. CA-125 Immune Complexes as Biomarkers of Ovarian Cancer
US8383607B2 (en) 2010-03-31 2013-02-26 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ， インコーポレイテッド Ａｃｔｒｉｉａ結合剤およびその使用
EP2793925B1 (en) 2011-12-19 2019-03-20 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
EP2802308A1 (en) 2012-01-13 2014-11-19 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
JP5782185B2 (ja) 2012-06-01 2015-09-24 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
KR101633727B1 (ko) 2016-06-28
US10407487B2 (en) 2019-09-10
US20160264644A1 (en) 2016-09-15
AR065611A1 (es) 2009-06-17
KR20120065374A (ko) 2012-06-20
US9809638B2 (en) 2017-11-07
NZ579369A (en) 2012-02-24
WO2008109167A2 (en) 2008-09-12
IL200605A (en) 2016-10-31
CN101679980A (zh) 2010-03-24
US20110183897A1 (en) 2011-07-28
KR20160075861A (ko) 2016-06-29
HUE032260T2 (en) 2017-09-28
CA2679841A1 (en) 2008-09-12
PL2132314T3 (pl) 2017-07-31
EA201490822A1 (ru) 2014-11-28
CN101679980B (zh) 2016-05-11
ES2613043T3 (es) 2017-05-22
CL2008000664A1 (es) 2008-06-13
PH12013502308A1 (en) 2015-12-02
AU2008223338C9 (en) 2013-07-04
EA020510B1 (ru) 2014-11-28
CR20150094A (es) 2015-04-14
US9447165B2 (en) 2016-09-20
WO2008109167A3 (en) 2009-06-18
US20140194355A1 (en) 2014-07-10
BRPI0808332A2 (pt) 2014-07-08
AU2008223338C1 (en) 2013-06-20
JP5496682B2 (ja) 2014-05-21
PE20130615A1 (es) 2013-07-01
KR20090127146A (ko) 2009-12-09
DK2132314T3 (en) 2017-02-27
CN105924516A (zh) 2016-09-07
US20180072791A1 (en) 2018-03-15
TW201441254A (zh) 2014-11-01
PE20081804A1 (es) 2009-02-21
TW201718635A (zh) 2017-06-01
EA200970810A1 (ru) 2010-06-30
EP3141605A1 (en) 2017-03-15
CA2679841C (en) 2022-03-08
KR101633728B1 (ko) 2016-06-28
SI2132314T1 (sl) 2017-03-31
LT2132314T (lt) 2017-03-27
HRP20170323T1 (hr) 2017-04-21
TWI454479B (zh) 2014-10-01
CY1118857T1 (el) 2018-01-10
EP2132314A2 (en) 2009-12-16
KR101428344B1 (ko) 2014-08-13
AU2008223338A1 (en) 2008-09-12
CR11054A (es) 2009-10-30
PT2132314T (pt) 2017-03-02
CN101679980B8 (zh) 2017-02-22
RS55726B1 (sr) 2017-07-31
CL2015003139A1 (es) 2016-07-15
MX389715B (es) 2025-03-20
IL248322A0 (en) 2016-11-30
AU2008223338B2 (en) 2012-12-20
TWI573802B (zh) 2017-03-11
MX2009009495A (es) 2009-09-15
US8716459B2 (en) 2014-05-06
JP2010519931A (ja) 2010-06-10
US20090227497A1 (en) 2009-09-10
US7947646B2 (en) 2011-05-24
KR20150024444A (ko) 2015-03-06
EP2132314B1 (en) 2016-11-30
KR20140056393A (ko) 2014-05-09
TW200846359A (en) 2008-12-01
IL200605A0 (en) 2011-08-01
PE20171325A1 (es) 2017-09-11

Similar Documents

Publication Publication Date Title
PH12013502308A1 (en) Variant activin receptor polypeptides and uses thereof
TN2011000238A1 (en) Variants of activin iib receptor polypeptides and uses thereof
HK1203384A1 (en) Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
ATE554101T1 (de) Neuer activinrezeptor und anwendungen davon
WO2008121767A3 (en) Stitched polypeptides
WO2008094708A3 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
WO2009012176A3 (en) Methods and compositions for treating brain diseases
WO2008088583A3 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2010009368A3 (en) Compositions for the detection and treatment of colorectal cancer
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
AU2010226726A8 (en) Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
WO2009020933A3 (en) Therapeutic use of anti-tweak receptor antibodies
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
WO2010132370A8 (en) Soluble trem-1 family peptides and methods of use
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
GB0524477D0 (en) Isolated T cell receptors which specifically bind to vygfvracl-hla-24
WO2007022273A3 (en) Vegf-activated fas ligands
WO2008103966A3 (en) Compositions and methods using toll-like receptors and unc93b
MY155313A (en) Variant activin receptor polypeptides and uses thereof
WO2006002854A3 (en) Tie receptor and tie ligand materials and methods for modulating female fertility
TW200602055A (en) Spray dried pharmaceutical compositions
TW200621265A (en) Composition for treating tumor and/or preventing tumor transfer and recurrence
WO2008067069A3 (en) Mitogen activated protein kinase phosphatase 4 (mkp4) and methods of use thereof